Eye­ing an ac­cel­er­at­ed BLA, Phase­Bio says its mon­o­clon­al an­ti­body re­versed the dan­ger­ous ef­fects of As­traZeneca's blood thin­ner

A class of blood thin­ners called P2Y12 in­hibitors has been used for the last cou­ple decades to treat and pre­vent a range of car­dio­vas­cu­lar con­di­tions, in­clud­ing stroke and heart at­tack. But the an­tiplatelet drugs come with a risk of in­creased bleed­ing, which can prove fa­tal — es­pe­cial­ly for those who need ur­gent surgery and don’t have time to wean off their med­ica­tion.

Phase­Bio is work­ing on a so­lu­tion for that. And on Mon­day, the com­pa­ny pre­sent­ed pos­i­tive Phase III da­ta that could pave the way for a mid-2022 BLA sub­mis­sion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER